Tesamorelin 10 mg
Also known as · TH9507 · Egrifta®
Tesamorelin is an approved GHRH analogue. The research-grade form is used widely in GH-axis, lipid-metabolism, and hepatic-fat research.
Chemistry quick-facts
- CAS
- 218949-48-5
- Formula
- C221H366N72O67S
- MW
- 5196 Da
- Length
- 44 aa
- Status
- Approved by the FDA (2010) for HIV-associated lipodystrophy under the brand name Egrifta® (Theratechnologies). Supplied by Omega Grade as research-grade peptide.
- Purity (HPLC)
- ≥ 99.0%
Mechanism of action
Agonism at the GHRH receptor → pituitary GH release → IGF-1 elevation. Mass-balance effects on visceral adipose tissue documented in HIV-lipodystrophy RCTs.
Research context
Tesamorelin (TH9507) is a stabilised 44-residue analogue of human GHRH, developed by Theratechnologies. The trans-3-hexenoyl N-terminal modification confers enzymatic stability.
FDA approved in 2010 for the reduction of excess abdominal fat in HIV-associated lipodystrophy. More recent clinical research has examined effects on NAFLD (non-alcoholic fatty liver disease).
Published studies
A non-exhaustive list of peer-reviewed studies referenced when curating this entry. Click through to the primary source for the full text.
- Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine.
- Stanley TL, Feldpausch MN, Oh J, et al. (2014). Effect of Tesamorelin on Visceral Fat and Liver Fat. JCEM.
Reconstitution
- Solvent
- Bacteriostatic water for injection (0.9% benzyl alcohol) — included with kit
- Typical volume
- 1 – 2 mL
- · Inject diluent slowly down the side of the vial onto the cake.
- · Swirl gently — do not shake.
- · Solution should be clear and colourless. Discard if not.
Storage
- Lyophilised
- −20 °C, desiccated, protected from light. Stable at 15–25 °C for up to 30 days in transit.
- Reconstituted
- 2–8 °C, original vial, consumed within 4 weeks.
- Shelf life — sealed
- 24 months from date of manufacture when stored lyophilised at −20 °C.
FAQ
How is this different from sermorelin?+
Sermorelin is GRF(1-29) — a shorter fragment of GHRH. Tesamorelin is GRF(1-44) with a trans-3-hexenoyl N-terminal modification for enzymatic stability. Tesamorelin reached approval; sermorelin was withdrawn.
This page summarises the research literature on Tesamorelin 10 mg for in vitro laboratory investigation only. It is not medical advice, not a treatment recommendation, and not a substitute for a qualified physician. Material is sold for analytical chemistry and cell-culture research, not for human or veterinary administration.
- ResearchCJC-1295 with DAC 5 mg
CJC-1295 with Drug Affinity Complex (DAC) — an extended GHRH analogue designed for half-life extension through covalent albumin binding.
- ResearchSermorelin 10 mg
Sermorelin is the 29-amino-acid N-terminal fragment of GHRH — the minimum sequence for full GH-releasing activity.
- ResearchIGF-1 LR3 1 mg
Long R3 IGF-1 — an engineered IGF-1 analogue with reduced affinity for IGF-binding proteins and extended plasma half-life. Widely used research reagen
- GlossaryGHRH
Growth hormone-releasing hormone, the hypothalamic peptide that triggers GH release.
- BiomarkerTSH 4.5 mIU/L
TSH at 4.5 mIU/L sits at the top edge of most printed reference ranges (typically 0.4–4.0). What that number indicates physiologically, why "high-normal" matters, and what the research literature looks at when this pattern appears.
- BiomarkerFree T3 low, TSH normal
Free T3 below the reference range with a normal TSH suggests your body isn't converting T4 into the active T3 hormone efficiently. The research literature on conversion problems and what they look like.